HCW Biologics Inc.
corporate_fare Company Profile
HCW Biologics Inc. (NASDAQ:HCWB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 65 items for HCWB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for HCWB spans PRE 14A, 10-Q, 8-K, S-1.
Recent high-impact activity:
- HCW Biologics Re-Runs Warrant Approvals for 1.52M Shares After Quorum Failure
- HCW Biologics 10-Q: $3.2M Q3 Loss, Two Unremediated Material Weaknesses, Going Concern Stands
- HCW Biologics Q3 2026: Net Loss Narrows to $3.2M, Going Concern Warning Reiterated
- HCW Biologics Posts $2.83 Per-Share Q3 Loss as Cash Crunch Deepens
- HCW Biologics Raises Up to $10M in Secured Debt From Streeterville Capital
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 49,290 shares in HCWB as of the October 30, 2026 settlement, a 30.7% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 15.7% of HCWB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for HCWB, detected from its recent SEC filings · based on capital-structure filings through 2026-09-24.
$1.5M Private Placement Priced · Warrant Structure Creates Dilution Overhang
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →